The American Society of Anesthesiologists released guidance on preoperative management of glucagon-like peptide-1 receptor agonists, and recent studies looked at the effects of semaglutide, retatrutide, and orforglipron on weight in patients with and without diabetes.
14 Jul 2023
The global age-standardized prevalence of diabetes is 6.1%, according to an analysis of 204 countries, while other recent studies found diabetes control in China and India to be less than optimal.
11 Aug 2023
Pharmaceutical manufacturers recently published studies on investigational basal insulin formulations that could be taken once a week by patients with type 1 or type 2 diabetes.
12 May 2023
A scientific statement from the American Heart Association offered guidance on the epidemiology of diabetes among Asian American people, while an analysis of the algorithms for predicting type 2 diabetes found that they make lower estimates of risk in Black patients than White.
9 Jun 2023
Manufacturer trials reported the effects of weekly insulin and teplizumab in patients with type 1 diabetes, while recent reviews looked at preventing beta-cell loss with various therapeutics and using drugs approved for type 2 diabetes to combat chronic kidney disease in type 1.
10 Nov 2023
Recent studies looked at how statins negatively affect glycemic control but improve cardiovascular mortality, as well as the reasons patients with diabetes don't receive prescriptions for statins despite recommendations.
14 Apr 2023
In patients with type 2 diabetes, a healthier lifestyle was associated with reduced risk of macrovascular and microvascular disease, one study found, while another showed the same for diabetic kidney disease and a third highlighted the benefits of leisure-time physical activity.
8 Sep 2023
One study found that physicians were unlikely to deprescribe hypoglycemia-causing medications in older diabetes patients, while others found suboptimal use of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and additional recommended medications.
10 Mar 2023
Two studies tried to determine whether COVID-19 infection leads to a subsequent increase in the risk of developing diabetes, while another highlighted how type 2 diabetes has risen among youth since the start of the pandemic.
10 Feb 2023
A large trial compared insulin, a sulfonylurea, a glucagon-like peptide-1 (GLP-1) receptor agonist, and a dipeptidyl peptidase-4 inhibitor as second-line therapy, while a modeling study considered GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors as first-line agents.
14 Oct 2022